Clinical trials: Proteinuric Diseases
Chronic Kidney Disease
Remission Clinic in Proteinuric Chronic Nephropathies
Most chronic kidney diseases have a progressive evolution characterized by the gradual loss of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis and activation of vitamin D.
- Trial name
- NCT02721342
- Testing
- Ramipril, Irbesartan and Atorvastin
- Where
- 13 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Heavy Proteinuria
Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.
- Trial name
- NCT00200694
- Testing
- ramipril 5 mg + valsartan 80 mg/day,, ramipril 10 mg + valsartan 160 mg/day,, ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Nantes University Hospital
Hypertension (HTN)
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
- Trial name
- NEPHRON (NCT07223502)
- Testing
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Proteinuria
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of graft failure.
- Trial name
- NCT02327403
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Proteinuric Diseases
Phenylbutyrate in Proteinuric Nephropathies
The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.
- Trial name
- PIRATE (NCT02343094)
- Testing
- PBA 7,5g/d, PBA 15g/d
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gestational Hypertension
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
The investigators do not know which approach to treatment of non-severe high blood pressure in pregnancy is better for women and babies.
- Trial name
- NCT01192412
- Testing
- Intervention is blood pressure management approach, Intervention is blood pressure management approach.
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 987 people
- Sponsor
- University of British Columbia
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Proteinuria
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.
- Trial name
- NCT01831193
- Testing
- Curcumin
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Diabetic Nephropathy
Minocycline and Proteinuria in Diabetic Nephropathy
Diabetic kidney disease increases the risk of illness and death from heart disease in patients with Type 2 diabetes. Some blood pressure medications called ACE inhibitors and ARBs slow progression of kidney disease, but the dose…
- Trial name
- NCT01779089
- Testing
- Minocycline 100 mg po bid for 6 months
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Pregnancy Complications, Proteinuria in Pregnancy
Sonoclot to Evaluate Thrombotic Risk in Proteinuric Pregnancy
There is a lack of consensus on whether women with proteinuric kidney disease benefit from prophylactic anticoagulation during pregnancy to reduce the risk of venous thromboembolism.
- Conditions
- Pregnancy Complications, Proteinuria in Pregnancy, Chronic Kidney Diseases, Venous Thromboembolism
- Trial name
- NCT05108389
- Testing
- Viscoelastic haemostasis monitor output
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Diabetes Mellitus, Type 2
How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?
Pioglitazone is an insulin sensitising drug used in the treatment of patients with type 2 diabetes. In addition to its blood sugar lowering effect, pioglitazone also has a number of other beneficial effects, one of which is to…
- Trial name
- NCT00749047
- Testing
- Pioglitazone
- Where
- New Zealand
- Volunteers
- 12 people
- Sponsor
- Christchurch Hospital
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose…
- Conditions
- Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria
- Trial name
- NCT00961207
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cook County Health
Diabetes, Hypertension
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
Diabetic nephropathy (DN) is the most important complication of diabetes mellitus (DM) and the most common cause of end-stage renal disease (ESRD).
- Conditions
- Diabetes, Hypertension, Proteinuria
- Trial name
- NCT00921570
- Testing
- Amlodipine, Valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Gulhane School of Medicine
Proteinuric Renal Disease
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes.
- Trial name
- NCT00469625
- Testing
- paricalcitol (initial dose 1 mcg orally per day)
- Where
- United States
- Sponsor
- Winthrop University Hospital
Renal Insufficiency, Chronic, Proteinuria
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (>65 years old) patients with non-proteinuric nephropathies.
- Trial name
- PROERCAN01 (NCT03195023)
- Testing
- Lisinopril, Amlodipine
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Proteinuric Kidney Disease
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
- Trial name
- AMPLIFIED (NCT06794996)
- Testing
- Inaxaplin
- Where
- 35 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
IGA Glomerulonephritis
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.
- Trial name
- NCT01115426
- Testing
- Ramipril or losartan
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University Magna Graecia